NCT07850921
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
StatusNot Yet Recruiting
PhasePhase 1/2
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 5 years
Occurrence of Dose-Limiting Toxicities (DLTs)
Timeframe: Up to 42 days
Occurrence of Serious Adverse Events (SAEs)
Timeframe: Up to 5 years
Occurrence of Adverse Events of Special Interests (AESIs)
Timeframe: Up to 5 years
Composite Response Rate (CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)
Timeframe: Up to 5 years
Secondary (12)
(CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)
Occurrence of TEAEs
Occurrence of SAEs
Occurrence of AESIs
Percentage of participants with ≥50% reduction in PSA confirmed by a second PSA test ≥3 weeks later
Show 7 moreShow less
Percentage of participants with ≥90% reduction in PSA confirmed by a second PSA test ≥3 weeks later
REGN21353 serum concentrations
Nezastomig serum concentrations
Occurrence of Anti-Drug Antibodies (ADA) to REGN21353
Occurrence of ADA to nezastomig
Magnitude of ADA to REGN21353
Magnitude of ADA to nezastomig
Arms and interventions
Module 1: monotherapyExperimental
Module 2: combinationExperimental
Drugs: REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)